首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1665279

血球容積比測試設備市場機會、成長動力、產業趨勢分析與預測 2025 - 2034

Hematocrit Test Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

出版日期: 2024年12月19日 | 出版商:

Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年全球血球容積比測試設備市場價值 38 億美元，預計 2025 年至 2034 年期間的複合年成長率為 4.4%。對精確、高效診斷工具的需求不斷成長，使得血球容積比測試設備成為醫療保健服務中的關鍵組成部分。

市場分為儀器、試劑和消耗品，其中儀器類別（包括血球比容測試分析儀和儀表）佔據領先地位。 2024年，該部門創造了最高收入，達22億美元。這些設備對於定期監測血球濃度是必不可少的，強調了它們在醫療和診斷環境中的必要性。

市場範圍
起始年份	2024
預測年份	2025-2034
起始值	38億美元
預測值	57億美元
複合年成長率	4.4％

此外，市場還根據測試類型進行分類，包括基於實驗室的測試和即時診斷（POC）測試。實驗室測試成為主導領域，2024 年的收入為 25 億美元。實驗室的血球容積比測試設備對於診斷貧血、紅血球增多症和脫水等一系列疾病至關重要，使其成為醫療診斷中必不可少的工具。

美國仍然是重要的市場參與者，其血細胞比容測試設備在 2024 年的收入為 14 億美元。預計該領域在 2025 年至 2034 年期間的複合年成長率為 3.9%。這些設備的應用涵蓋臨床和家庭醫療保健環境，確保它們在患者監測和護理中發揮關鍵作用。

產業生態系統分析
產業衝擊力
- 成長動力
  - 血液疾病盛行率不斷上升
  - 對即時診斷檢測的需求不斷成長
  - 血液學檢測的技術進步
- 產業陷阱與挑戰
  - 先進的血球比容儀價格昂貴
成長潛力分析
監管格局
技術格局
波特的分析
PESTEL 分析
差距分析
未來市場趨勢
價值鏈分析

第4章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
主要市場參與者的競爭分析
競爭定位矩陣
策略儀表板

第 5 章：市場估計與預測：按產品，2021 年至 2034 年

主要趨勢
儀器
- 血球容積比測試分析儀
- 血球容積比測試儀
試劑和耗材

第 6 章：市場估計與預測：按模式，2021 年至 2034 年

主要趨勢
實驗室檢測
即時診斷（POC）檢測

第 7 章：市場估計與預測：按應用，2021 年至 2034 年

主要趨勢
貧血
先天性心臟病
真性紅血球增多症
其他應用

第 8 章：市場估計與預測：依最終用途，2021 年至 2034 年

主要趨勢
醫院
診斷實驗室
門診手術中心
其他最終用戶

第 9 章：市場估計與預測：按地區，2021 年至 2034 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國

第10章：公司簡介

MENARINI Group
Abbott
BIO-RAD
Boule
Danaher
Diatron
EKF Diagnostics
Roche
HORIBA Medical
Mindray
NIHON KOHDEN
Nova Biomedical
SENSA CORE
SIEMENS Healthineers
Sysmex

簡介目錄

Product Code: 12760

The Global Hematocrit Test Devices Market was valued at USD 3.8 billion in 2024 and is projected to expand at a CAGR of 4.4% from 2025 to 2034. This robust growth is driven by a rising prevalence of blood disorders, a growing aging population, and continuous advancements in point-of-care testing technologies. The increasing demand for precise and efficient diagnostic tools positions hematocrit test devices as a critical component in healthcare delivery.

The market is segmented into instruments, reagents, and consumables, with the instruments category-comprising hematocrit test analyzers and meters-leading the charge. In 2024, this segment generated the highest revenue of USD 2.2 billion. These devices are indispensable for the regular monitoring of blood cell concentrations, underscoring their necessity in both medical and diagnostic settings.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$3.8 Billion
Forecast Value	$5.7 Billion
CAGR	4.4%

Additionally, the market is categorized by testing type, including laboratory-based testing and point-of-care (POC) testing. Laboratory-based testing emerged as the dominant segment, accounting for USD 2.5 billion in revenue in 2024. With a projected CAGR of 4.2% from 2025 to 2034, this segment continues to thrive due to its ability to deliver highly precise and reliable results. Laboratory-based hematocrit testing devices are crucial for diagnosing a range of conditions, such as anemia, polycythemia, and dehydration, making them an essential tool in healthcare diagnostics.

The U.S. remains a significant market player, with hematocrit test devices generating USD 1.4 billion in revenue in 2024. This segment is forecasted to grow at a CAGR of 3.9% between 2025 and 2034. The increasing prevalence of blood disorders, such as anemia, sickle cell disease, and polycythemia, within the U.S. population fuels the demand for reliable hematocrit testing equipment. The adoption of these devices spans clinical and home healthcare settings, ensuring their pivotal role in patient monitoring and care.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of blood disorders
  - 3.2.1.2 Growing demand for point-of-care testing
  - 3.2.1.3 Technological advancements in hematology testing
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of advanced hematocrit devices
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technology landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
3.8 Gap analysis
3.9 Future market trends
3.10 Value chain analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

5.1 Key trends
5.2 Instruments
- 5.2.1 Hematocrit test analyzer
- 5.2.2 Hematocrit test meter
5.3 Reagents and consumables

Chapter 6 Market Estimates and Forecast, By Modality, 2021 – 2034 ($ Mn)

6.1 Key trends
6.2 Laboratory-based testing
6.3 Point-of-care (POC) testing

Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

7.1 Key trends
7.2 Anemia
7.3 Congenital heart diseases
7.4 Polycythemia vera
7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Diagnostic laboratories
8.4 Ambulatory surgical centers
8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE